合并巨大左心室心脏瓣膜疾病外科治疗的临床研究
|
摘要
研究背景:
心脏瓣膜疾病是常见的心脏疾病,在我国发病率较高。心脏瓣膜置换手术是治疗瓣膜疾病最有效的方法,随着对瓣膜疾病的认识水平、瓣膜置换技术、心肌保护技术、体外循环技术、围手术期并发症防治水平以及瓣膜工艺水平等的提高,心脏瓣膜置换手术的疗效有了显著提高,但对于合并巨大左室的重症心脏瓣膜疾病,手术后早期并发症发生率和死亡率仍明显较高,有关其远期疗效的报道也不尽相同。对于重症心脏瓣膜疾病患者,术中心肌保护仍是心脏外科研究的热点问题,目前在合并主动脉瓣关闭不全的巨大左室心脏瓣膜置换手术中,多采用冠状静脉窦逆行灌注的心肌保护方法,而由于传统观念影响,经冠状动脉直接顺行灌注的心肌保护方法在临床应用甚少。
本研究旨在回顾分析巨大左室心脏瓣膜置换手术后早期死亡的危险因素;探讨巨大左室心脏瓣膜置换手术的最佳心肌保护方法;随访分析巨大左室心脏瓣膜置换手术后远期疗效和抗凝治疗情况及其影响因素。
研究方法:
第一部分为临床回顾性研究,应用Microsoft Access XP数据库和SPSS 10.0统计软件,收集1996年1月至2005年4月我院157例合并巨大左室心脏瓣膜置换手术患者的临床资料。重点分析患者性别、病因、基础病变、手术类型、手术方式、所用瓣膜类型、心肌保护方式、体外循环转流时间、阻断主动脉时问以及手术并发症等因素对手术早期死亡的影响。
第二部分为前瞻性研究,探讨采用不同心肌保护方法对2005年5月至2006年10月我院18例合并巨大左室心脏瓣膜置换手术的心肌保护效果。全部选择男性病例,按不同手术类型随机分为两组:冷血冠状动脉间断顺行灌注(顺灌组)和冷血冠状静脉窦逆行灌注(逆灌组),每组9例。观察指标:临床疗效(包括并发症及早期死亡情况、心功能等级、超声检查左室舒张末期直径、左室射血分数和左室缩短指数),肌酸激酶同工酶MB(CKMB),心肌肌钙蛋白I(cTnI),血乳酸含量,心肌氧摄取率等。
第三部分为临床前瞻性研究,采用门诊复查、电话随访和信件随访相结合的办法,对我院1996年1月至2005年4月实施巨大左室心脏瓣膜置换手术后早期存活的146例患者进行远期疗效和抗凝治疗情况随访,并分析影响其远期存活率和疗效的危险因素,临床疗效评价指标有:心功能等级、病人对疗效的自我评价、严重不良事件发生情况等。心脏超声检查主要评价左室舒张末期直径、左室射血分数和左室缩短指数等。
研究结果:
第一部分结果:
1、合并巨大左室心脏瓣膜置换手术157例,早期死亡率为7.01%(11/157),明显高于同期非巨大左室心脏瓣膜置换手术组(p＜0.05),后者早期死亡率为1.56%(21/1350)。
2、单因素分析结果显示:男性病人、病因为感染性心内膜炎、术前心功能Ⅳ级、左室舒张末期直径≥8.0cm、左室射血分数＜50%或左室缩短指数＜30%、双瓣膜置换、体外循环转流时间＞130分钟、阻断主动脉时间＞90分钟、冠状静脉窦逆行灌注心肌保护组巨大左室心脏瓣膜置换手术后早期死亡率升高,提示上述因素可能是早期死亡的危险因素。
3、手术早期死亡原因分析显示,巨大左室心脏瓣膜置换手术后早期死亡原因分别为室颤、低心输出量综合征和多脏器功能衰竭。室颤、心脏骤停死亡6例,占54.54%(6/11),为首位死亡原因。
第二部分结果:
1、18例巨大左室心脏瓣膜置换手术患者早期死亡2例,顺灌组和逆灌组各1例,其余患者治愈出院。两组患者体外循环转流时间、阻断主动脉时间、术后并发症发生情况、呼吸机辅助时间、住院时间、心功能恢复情况均无明显差异(p＞0.05)。心脏超声检查显示两组左室舒张末期直径均较术前缩小(p＜0.05),而顺灌组术后左室功能恢复更好。
2、两组患者阻断主动脉前血清CK-MB和cTnI浓度就比术前1天明显升高(p＜0.05),阻断主动脉后进一步升高,到手术后第1天达到高峰,手术后第3天恢复到阻断主动脉前水平。顺灌组在开放主动脉10分钟和手术后第1天血清CK-MB和cTnI浓度低于逆灌组(p＜0.05)。
3、两组患者阻断主动脉40分钟心肌氧摄取率均明显降低,和阻断主动脉前比较差异显著(p＜0.05),两组间比较无差异(p＞0.05)。开放主动脉10分钟心肌氧摄取率有所升高,但仍低于阻断主动脉前(p＜0.05),顺灌组心肌氧摄取率略高于逆灌组,但无统计学差异(p＞0.05)。
4、两组患者阻断主动脉后动脉血和冠脉回血乳酸含量均较阻断前明显增加(p＜0.05),顺灌组在开放主动脉10分钟时动脉血和冠脉回血乳酸含量低于逆灌组(p＜0.05)。乳酸摄取率(负值)与乳酸变化趋势基本一致。
第三部分结果:
1、远期随访125例,失访21例,平均随访3.29年,累计随访412人年。巨大左室心脏瓣膜置换手术后主要并发症有心律失常、心功能衰竭、出血、栓塞和感染性心内膜炎。远期死亡10例,远期死亡率为2.43%病人·年,主要死亡原因为室颤和不明原因猝死。
2、远期随访结果显示,巨大左室心脏瓣膜置换手术后91.30%的患者心功能恢复至Ⅰ—Ⅱ级,较术前明显改善(p＜0.05),98.26%的患者自觉手术有效;双瓣膜置换手术后心功能Ⅲ—Ⅳ级比例高于二尖瓣置换组和主动脉瓣置换组(p＜0.05)。心脏超声随访发现远期存活115例患者左室舒张末期直径较术前明显缩小(p＜0.05);左室射血分数和左室缩短指数较术前有明显改善(p＜0.05),双瓣膜置换手术患者左室功能改善不如二尖瓣置换组和主动脉瓣置换组(p＜0.05)。
3、单因素分析结果显示男性、术前左室功能低下、双瓣膜置换手术患者巨大左室心脏瓣膜置换手术后远期死亡率较高(p＜0.05)。不定期检测抗凝水平的患者远期抗凝相关并发症发生率较高(p＜0.05)。
结论:
1、合并巨大左室心脏瓣膜置换手术早期死亡率明显较高,但是其整体疗效仍较为满意。男性患者、感染性心内膜炎、术前心功能差、双瓣膜置换手术、体外循环转流时间和主动脉阻断时间过长等是早期死亡危险因素。早期死亡的原因主要有室颤、低心输出量综合征和多脏器功能衰竭。
2、准确把握手术时机,良好的术中心肌保护,熟练而规范的手术处理,积极而合理的并发症防治是提高巨大左室心脏瓣膜置换手术后早期疗效的关键。
3、在巨大左室心脏瓣膜置换手术中,相比于冠状静脉窦逆行灌注的心肌保护,采用冠状动脉顺行灌注手术后早期心脏功能恢复较好,心肌损伤减轻,心肌代谢维持较好,是一种方便、可行、效果良好的心肌保护方法。
4、合并巨大左室心脏瓣膜置换手术后远期疗效较好。男性病例、双瓣膜置换、术前心功能差是手术后远期死亡的危险因素。远期死亡原因主要有室颤、顽固性心功能衰竭、抗凝出血和感染性心内膜炎。不定期检测抗凝水平的患者远期抗凝相关并发症发生率较高。
5、加强术后心功能支持治疗,积极防治术后心律失常,严格定期随访制度有助于降低巨大左室心脏瓣膜置换手术后远期并发症发生率,提高远期疗效。
Background:
Heart valve disease is common in China and the incidence is very high.Heart valve replacement is the most effective way to treat this disease.As the knowledge of this disease, the surgical technique,myocardial protection technique,extracorporeal circulation,and treatment of the preoperational complications are improved,the outcome of the heart valve replacement has become better.However,the incidence of the complications and the mortality in the early time after operation are still high,and the results about the late efficacy are different.In the severe patients with heart valve disease,the myocardial protection during the operation is still the focus.At present,retrograde cardioplegia via coronary sinus is usually used in the heart valve replacement in patients with aortic insufficiency combined with large left ventricle.Because of the influence of the traditional ideas,the antegrade cardioplegia is used unusually.
The present study is to analyze the risk factors of the mortality in the early time after the heart valve replacement in patients with large left ventricle retrospectively,to investigate the best myocardial protective way,to analyze the late efficacy and the anticoagulation through follow-up.
Methods:
The first part of this study is clinic retrospective research.The SPSS 10.0 statistical software was used in this part.Clinic materials were collected in157 patients with heart valve replacement combined with large left ventricle from January,1996 to April,2005. The sexuality,etiological factors,pathological characters,operation mode,the type of mechanical valve,myocardial protection way,the duration of the extracorporeal circulation, the time of aortic clamping and complications were analyzed for the mortality early after operation.
The second part is the prospective study.The efficacy of the different myocardial protection ways was investigated in 18 cases of heart valve replacement combined with large left ventricle.All the patients in this part were male,who were divided into two groups,including the intermittent antegrade cardioplegia group and the retrograde cardioplegia group.There were 9 patients in each group.The observing markers included clinical efficacy(complication and early mortality,NYHA classification,the diameter of the left ventricle at the end of the diastolic phase,the EF and the FS from echo),CK-MB, cTnI,lactic acid concentration in blood,MVO_2.
The last part is also prospective research.146 surviving patients with heart valve replacement combined with large left ventricle from January,1996 to April,2005 were followed up for the late efficacy and anticoagulation with the methods,like reexamination and follow up through telephone or letter.The risk factors affecting the late surviving incidence and the efficacy were analyzed.The evaluation indexes of the clinical efficacy included the NYHA classification,the self-evaluation on the efficacy from the patients,the occurrence of the severe events.The echocardiography was used to detect the diameter of the left ventricle at the end of the diastolic phase,the EF and the FS.
Results:
The first part:
1.The early mortality in 157 patients was 7.01%(11/157),which was much higher than that in patients(1.56%(21/1350) ) with heart valve replacement and without large left ventricle(p＜0.05).
2.The risk factors for the early death after operation included male,infective endocarditis,NYHAⅣcardiac function,the diameter of the left ventricle at end of the diastolic phase≥8.0cm,EF of the left ventricle＜50%or the FS＜30%,double valve replacement,the time of cardiopulmonary bypass＞130min,the time of aortic clamping＞90min and retrograde cardioplegia.
3.The analysis for the cause of the early death showed that ventricular fibrillation,low cardiac output syndrome and MODS were the main causes of the early death in these patients.6 patients died of ventricular fibrillation and heart arrest(54.54%(6/11) ),which was the capital cause of the early death.
The second part:
1.2 patients from the two groups died early after heart valve replacement in all the 18 patients with lager left ventricle.The other patients recovered well.There were no significant difference in cardiopulmonary bypass time,the time of aortic clamping, complication after operation,ventilation assisting time,hospital time,recover of cardiac function between the two groups(p＞0.05).The echo showed that the diameter of the left ventricle at the end of the diastolic phase decreased compared to that before operation (p＜0.05).The cardiac function of patients in the antegrade cardioplegia group recovered better.
2.Serum CK-MB and cTnI levels before aortic clamping were higher than those before operation in the two groups(p＜0.05).After the clamp,the levels increased further and get to the peak at the first day after operation.At the third day after operation,these two markers returned to the levels before the aortic clamping.The antegrade cardioplegia group had the lower serum concentration of CK-MB and cTnI on the 10~(th) min after the opening of aorta and the first day after operation,compared to the retrograde cardioplegia group.
3.The MVO_2 decreased significantly 40 min after the aortic clamping in the two groups(p＜0.05).The MVO_2 increased 10min after the opening of the aorta,which was lower than that before the clamping(p＜0.05).The MVO_2 in the antegrade cardioplegia group was little higher than that in the retrograde cardioplegia group,but the difference was not significant(p＞0.05).
4.The lactic acid concentration in arterial blood and the blood from coronary sinus was much higher after the clamping than before the clamping(p＜0.05).The lactic acid concentration in the antegrade cardioplegia group was lower than that in the retrograde cardioplegia group at the 10~(th) min after the opening of the aorta(p＜0.05).
The third part:
1.125 patients were successfully followed up in 146 patients.The average follow-up time was 3.29 years.The main complications after heart valve replacement in patients with large left ventricle included arrhythmia and decreasing of the cardiac function,bleeding, embolism and infective endocarditis.10 patients died and the late mortality was 2.43%pt-yr. One of the causes of death was ventricular fibrillation.However,some patients suddenly died of unknown events.
2.The results of follow-up showed that 91.30%of all the patients got the better cardiac function(NYHAⅠ-Ⅱ),compared to that before operation(p＜0.05 ),98.26%of all the patients thought that the treatment was effective.The proportion of NYHAⅢ-Ⅳcardiac function in the patients with double valve replacement was higher than that in the patients with mitral or aortic valve replacement(p＜0.05).The echo showed that 115 surviving patients had the smaller left ventricle,compared to that before operation(p＜0.05).EF and FS were improved significantly,too(p＜0.05).However,the improvement of cardiac function in patients with double valve replacement was less than that in patients with mitral or aortic valve replacement(p＜0.05).
3.It was found that male patients,dysfunction of left ventricle and double valve replacement led to the higher late mortality(p＜0.05) Irregular monitoring of anticoagulation led to the higher incidence of anticoagulation related complications (p＜0.05)
Conclusions:
1.The early mortality was high in this group of patients with large left ventricle after heart valve replacement,but the outcome was still satisfactory.The risk factors for the early death after operation included male patients,infective endocarditis,dysfunction of the heart, double valve replacement,and the long duration of cardiopulmonary bypass and aortic clamping.The main causes of the early death included ventricular fibrillation,low cardiac output syndrome and MODS.
2.The key measures to improve the early treatment efficacy in patients with large left ventricle after heart valve replacement included the accurate opportunity of operation, satisfactory myocardial protection,proficient surgical skills,active and reasonable prevention and treatment of complications.
3.In the patients with large left ventricle and undergoing heart valve replacement,the antegrade cardioplegia through coronary artery could led to the better recovery of cardiac function,the lighter myocardial injury and better maintenance of the myocardiac metabolism,compared to the retrograde cardioplegia through coronary sinus.Therefore, antegrade cardioplegia through coronary artery is a convenient and effective cardioprotective way.
4.The late efficacy of this group of patients was fairly satisfactory.The risk factors for the late death included male patients,double valve replacement,dysfunction of the heart before operation.The main causes of the late death included ventricular fibrillation, refractory heart failure,bleeding caused by coagulation,and infective endocarditis. Irregular monitoring of coagulation caused higher incidence of coagulation related complications.
5.The active support of the cardiac function after operation,the prevention and cure of arrhythmia,regular follow-up could help lower the incidence of the late complications and improve the late efficacy.
心脏瓣膜疾病是常见的心脏疾病,在我国发病率较高。心脏瓣膜置换手术是治疗瓣膜疾病最有效的方法,随着对瓣膜疾病的认识水平、瓣膜置换技术、心肌保护技术、体外循环技术、围手术期并发症防治水平以及瓣膜工艺水平等的提高,心脏瓣膜置换手术的疗效有了显著提高,但对于合并巨大左室的重症心脏瓣膜疾病,手术后早期并发症发生率和死亡率仍明显较高,有关其远期疗效的报道也不尽相同。对于重症心脏瓣膜疾病患者,术中心肌保护仍是心脏外科研究的热点问题,目前在合并主动脉瓣关闭不全的巨大左室心脏瓣膜置换手术中,多采用冠状静脉窦逆行灌注的心肌保护方法,而由于传统观念影响,经冠状动脉直接顺行灌注的心肌保护方法在临床应用甚少。
本研究旨在回顾分析巨大左室心脏瓣膜置换手术后早期死亡的危险因素;探讨巨大左室心脏瓣膜置换手术的最佳心肌保护方法;随访分析巨大左室心脏瓣膜置换手术后远期疗效和抗凝治疗情况及其影响因素。
研究方法:
第一部分为临床回顾性研究,应用Microsoft Access XP数据库和SPSS 10.0统计软件,收集1996年1月至2005年4月我院157例合并巨大左室心脏瓣膜置换手术患者的临床资料。重点分析患者性别、病因、基础病变、手术类型、手术方式、所用瓣膜类型、心肌保护方式、体外循环转流时间、阻断主动脉时问以及手术并发症等因素对手术早期死亡的影响。
第二部分为前瞻性研究,探讨采用不同心肌保护方法对2005年5月至2006年10月我院18例合并巨大左室心脏瓣膜置换手术的心肌保护效果。全部选择男性病例,按不同手术类型随机分为两组:冷血冠状动脉间断顺行灌注(顺灌组)和冷血冠状静脉窦逆行灌注(逆灌组),每组9例。观察指标:临床疗效(包括并发症及早期死亡情况、心功能等级、超声检查左室舒张末期直径、左室射血分数和左室缩短指数),肌酸激酶同工酶MB(CKMB),心肌肌钙蛋白I(cTnI),血乳酸含量,心肌氧摄取率等。
第三部分为临床前瞻性研究,采用门诊复查、电话随访和信件随访相结合的办法,对我院1996年1月至2005年4月实施巨大左室心脏瓣膜置换手术后早期存活的146例患者进行远期疗效和抗凝治疗情况随访,并分析影响其远期存活率和疗效的危险因素,临床疗效评价指标有:心功能等级、病人对疗效的自我评价、严重不良事件发生情况等。心脏超声检查主要评价左室舒张末期直径、左室射血分数和左室缩短指数等。
研究结果:
第一部分结果:
1、合并巨大左室心脏瓣膜置换手术157例,早期死亡率为7.01%(11/157),明显高于同期非巨大左室心脏瓣膜置换手术组(p＜0.05),后者早期死亡率为1.56%(21/1350)。
2、单因素分析结果显示:男性病人、病因为感染性心内膜炎、术前心功能Ⅳ级、左室舒张末期直径≥8.0cm、左室射血分数＜50%或左室缩短指数＜30%、双瓣膜置换、体外循环转流时间＞130分钟、阻断主动脉时间＞90分钟、冠状静脉窦逆行灌注心肌保护组巨大左室心脏瓣膜置换手术后早期死亡率升高,提示上述因素可能是早期死亡的危险因素。
3、手术早期死亡原因分析显示,巨大左室心脏瓣膜置换手术后早期死亡原因分别为室颤、低心输出量综合征和多脏器功能衰竭。室颤、心脏骤停死亡6例,占54.54%(6/11),为首位死亡原因。
第二部分结果:
1、18例巨大左室心脏瓣膜置换手术患者早期死亡2例,顺灌组和逆灌组各1例,其余患者治愈出院。两组患者体外循环转流时间、阻断主动脉时间、术后并发症发生情况、呼吸机辅助时间、住院时间、心功能恢复情况均无明显差异(p＞0.05)。心脏超声检查显示两组左室舒张末期直径均较术前缩小(p＜0.05),而顺灌组术后左室功能恢复更好。
2、两组患者阻断主动脉前血清CK-MB和cTnI浓度就比术前1天明显升高(p＜0.05),阻断主动脉后进一步升高,到手术后第1天达到高峰,手术后第3天恢复到阻断主动脉前水平。顺灌组在开放主动脉10分钟和手术后第1天血清CK-MB和cTnI浓度低于逆灌组(p＜0.05)。
3、两组患者阻断主动脉40分钟心肌氧摄取率均明显降低,和阻断主动脉前比较差异显著(p＜0.05),两组间比较无差异(p＞0.05)。开放主动脉10分钟心肌氧摄取率有所升高,但仍低于阻断主动脉前(p＜0.05),顺灌组心肌氧摄取率略高于逆灌组,但无统计学差异(p＞0.05)。
4、两组患者阻断主动脉后动脉血和冠脉回血乳酸含量均较阻断前明显增加(p＜0.05),顺灌组在开放主动脉10分钟时动脉血和冠脉回血乳酸含量低于逆灌组(p＜0.05)。乳酸摄取率(负值)与乳酸变化趋势基本一致。
第三部分结果:
1、远期随访125例,失访21例,平均随访3.29年,累计随访412人年。巨大左室心脏瓣膜置换手术后主要并发症有心律失常、心功能衰竭、出血、栓塞和感染性心内膜炎。远期死亡10例,远期死亡率为2.43%病人·年,主要死亡原因为室颤和不明原因猝死。
2、远期随访结果显示,巨大左室心脏瓣膜置换手术后91.30%的患者心功能恢复至Ⅰ—Ⅱ级,较术前明显改善(p＜0.05),98.26%的患者自觉手术有效;双瓣膜置换手术后心功能Ⅲ—Ⅳ级比例高于二尖瓣置换组和主动脉瓣置换组(p＜0.05)。心脏超声随访发现远期存活115例患者左室舒张末期直径较术前明显缩小(p＜0.05);左室射血分数和左室缩短指数较术前有明显改善(p＜0.05),双瓣膜置换手术患者左室功能改善不如二尖瓣置换组和主动脉瓣置换组(p＜0.05)。
3、单因素分析结果显示男性、术前左室功能低下、双瓣膜置换手术患者巨大左室心脏瓣膜置换手术后远期死亡率较高(p＜0.05)。不定期检测抗凝水平的患者远期抗凝相关并发症发生率较高(p＜0.05)。
结论:
1、合并巨大左室心脏瓣膜置换手术早期死亡率明显较高,但是其整体疗效仍较为满意。男性患者、感染性心内膜炎、术前心功能差、双瓣膜置换手术、体外循环转流时间和主动脉阻断时间过长等是早期死亡危险因素。早期死亡的原因主要有室颤、低心输出量综合征和多脏器功能衰竭。
2、准确把握手术时机,良好的术中心肌保护,熟练而规范的手术处理,积极而合理的并发症防治是提高巨大左室心脏瓣膜置换手术后早期疗效的关键。
3、在巨大左室心脏瓣膜置换手术中,相比于冠状静脉窦逆行灌注的心肌保护,采用冠状动脉顺行灌注手术后早期心脏功能恢复较好,心肌损伤减轻,心肌代谢维持较好,是一种方便、可行、效果良好的心肌保护方法。
4、合并巨大左室心脏瓣膜置换手术后远期疗效较好。男性病例、双瓣膜置换、术前心功能差是手术后远期死亡的危险因素。远期死亡原因主要有室颤、顽固性心功能衰竭、抗凝出血和感染性心内膜炎。不定期检测抗凝水平的患者远期抗凝相关并发症发生率较高。
5、加强术后心功能支持治疗,积极防治术后心律失常,严格定期随访制度有助于降低巨大左室心脏瓣膜置换手术后远期并发症发生率,提高远期疗效。
Background:
Heart valve disease is common in China and the incidence is very high.Heart valve replacement is the most effective way to treat this disease.As the knowledge of this disease, the surgical technique,myocardial protection technique,extracorporeal circulation,and treatment of the preoperational complications are improved,the outcome of the heart valve replacement has become better.However,the incidence of the complications and the mortality in the early time after operation are still high,and the results about the late efficacy are different.In the severe patients with heart valve disease,the myocardial protection during the operation is still the focus.At present,retrograde cardioplegia via coronary sinus is usually used in the heart valve replacement in patients with aortic insufficiency combined with large left ventricle.Because of the influence of the traditional ideas,the antegrade cardioplegia is used unusually.
The present study is to analyze the risk factors of the mortality in the early time after the heart valve replacement in patients with large left ventricle retrospectively,to investigate the best myocardial protective way,to analyze the late efficacy and the anticoagulation through follow-up.
Methods:
The first part of this study is clinic retrospective research.The SPSS 10.0 statistical software was used in this part.Clinic materials were collected in157 patients with heart valve replacement combined with large left ventricle from January,1996 to April,2005. The sexuality,etiological factors,pathological characters,operation mode,the type of mechanical valve,myocardial protection way,the duration of the extracorporeal circulation, the time of aortic clamping and complications were analyzed for the mortality early after operation.
The second part is the prospective study.The efficacy of the different myocardial protection ways was investigated in 18 cases of heart valve replacement combined with large left ventricle.All the patients in this part were male,who were divided into two groups,including the intermittent antegrade cardioplegia group and the retrograde cardioplegia group.There were 9 patients in each group.The observing markers included clinical efficacy(complication and early mortality,NYHA classification,the diameter of the left ventricle at the end of the diastolic phase,the EF and the FS from echo),CK-MB, cTnI,lactic acid concentration in blood,MVO_2.
The last part is also prospective research.146 surviving patients with heart valve replacement combined with large left ventricle from January,1996 to April,2005 were followed up for the late efficacy and anticoagulation with the methods,like reexamination and follow up through telephone or letter.The risk factors affecting the late surviving incidence and the efficacy were analyzed.The evaluation indexes of the clinical efficacy included the NYHA classification,the self-evaluation on the efficacy from the patients,the occurrence of the severe events.The echocardiography was used to detect the diameter of the left ventricle at the end of the diastolic phase,the EF and the FS.
Results:
The first part:
1.The early mortality in 157 patients was 7.01%(11/157),which was much higher than that in patients(1.56%(21/1350) ) with heart valve replacement and without large left ventricle(p＜0.05).
2.The risk factors for the early death after operation included male,infective endocarditis,NYHAⅣcardiac function,the diameter of the left ventricle at end of the diastolic phase≥8.0cm,EF of the left ventricle＜50%or the FS＜30%,double valve replacement,the time of cardiopulmonary bypass＞130min,the time of aortic clamping＞90min and retrograde cardioplegia.
3.The analysis for the cause of the early death showed that ventricular fibrillation,low cardiac output syndrome and MODS were the main causes of the early death in these patients.6 patients died of ventricular fibrillation and heart arrest(54.54%(6/11) ),which was the capital cause of the early death.
The second part:
1.2 patients from the two groups died early after heart valve replacement in all the 18 patients with lager left ventricle.The other patients recovered well.There were no significant difference in cardiopulmonary bypass time,the time of aortic clamping, complication after operation,ventilation assisting time,hospital time,recover of cardiac function between the two groups(p＞0.05).The echo showed that the diameter of the left ventricle at the end of the diastolic phase decreased compared to that before operation (p＜0.05).The cardiac function of patients in the antegrade cardioplegia group recovered better.
2.Serum CK-MB and cTnI levels before aortic clamping were higher than those before operation in the two groups(p＜0.05).After the clamp,the levels increased further and get to the peak at the first day after operation.At the third day after operation,these two markers returned to the levels before the aortic clamping.The antegrade cardioplegia group had the lower serum concentration of CK-MB and cTnI on the 10~(th) min after the opening of aorta and the first day after operation,compared to the retrograde cardioplegia group.
3.The MVO_2 decreased significantly 40 min after the aortic clamping in the two groups(p＜0.05).The MVO_2 increased 10min after the opening of the aorta,which was lower than that before the clamping(p＜0.05).The MVO_2 in the antegrade cardioplegia group was little higher than that in the retrograde cardioplegia group,but the difference was not significant(p＞0.05).
4.The lactic acid concentration in arterial blood and the blood from coronary sinus was much higher after the clamping than before the clamping(p＜0.05).The lactic acid concentration in the antegrade cardioplegia group was lower than that in the retrograde cardioplegia group at the 10~(th) min after the opening of the aorta(p＜0.05).
The third part:
1.125 patients were successfully followed up in 146 patients.The average follow-up time was 3.29 years.The main complications after heart valve replacement in patients with large left ventricle included arrhythmia and decreasing of the cardiac function,bleeding, embolism and infective endocarditis.10 patients died and the late mortality was 2.43%pt-yr. One of the causes of death was ventricular fibrillation.However,some patients suddenly died of unknown events.
2.The results of follow-up showed that 91.30%of all the patients got the better cardiac function(NYHAⅠ-Ⅱ),compared to that before operation(p＜0.05 ),98.26%of all the patients thought that the treatment was effective.The proportion of NYHAⅢ-Ⅳcardiac function in the patients with double valve replacement was higher than that in the patients with mitral or aortic valve replacement(p＜0.05).The echo showed that 115 surviving patients had the smaller left ventricle,compared to that before operation(p＜0.05).EF and FS were improved significantly,too(p＜0.05).However,the improvement of cardiac function in patients with double valve replacement was less than that in patients with mitral or aortic valve replacement(p＜0.05).
3.It was found that male patients,dysfunction of left ventricle and double valve replacement led to the higher late mortality(p＜0.05) Irregular monitoring of anticoagulation led to the higher incidence of anticoagulation related complications (p＜0.05)
Conclusions:
1.The early mortality was high in this group of patients with large left ventricle after heart valve replacement,but the outcome was still satisfactory.The risk factors for the early death after operation included male patients,infective endocarditis,dysfunction of the heart, double valve replacement,and the long duration of cardiopulmonary bypass and aortic clamping.The main causes of the early death included ventricular fibrillation,low cardiac output syndrome and MODS.
2.The key measures to improve the early treatment efficacy in patients with large left ventricle after heart valve replacement included the accurate opportunity of operation, satisfactory myocardial protection,proficient surgical skills,active and reasonable prevention and treatment of complications.
3.In the patients with large left ventricle and undergoing heart valve replacement,the antegrade cardioplegia through coronary artery could led to the better recovery of cardiac function,the lighter myocardial injury and better maintenance of the myocardiac metabolism,compared to the retrograde cardioplegia through coronary sinus.Therefore, antegrade cardioplegia through coronary artery is a convenient and effective cardioprotective way.
4.The late efficacy of this group of patients was fairly satisfactory.The risk factors for the late death included male patients,double valve replacement,dysfunction of the heart before operation.The main causes of the late death included ventricular fibrillation, refractory heart failure,bleeding caused by coagulation,and infective endocarditis. Irregular monitoring of coagulation caused higher incidence of coagulation related complications.
5.The active support of the cardiac function after operation,the prevention and cure of arrhythmia,regular follow-up could help lower the incidence of the late complications and improve the late efficacy.
引文
1.刘维永.心脏瓣膜外科的现状和发展趋势[J].中国胸心血管外科临床志,1999,6(2):65-66.
2.张宝仁,邹良建,徐志云,等.风湿性瓣膜病二尖瓣与主动脉瓣置换术1154例长期效果分析[J].中华外科杂志,2003,41(4):243-246.
3.Kang CH,Ahn H,Kim KH.Long-term result of 1144 CarboMedics mechanical valve implantations[J].Ann Thorac Surg,2005,79(6):1939-1944.
4.John S,Ravikumar E,John CN,et al.25-year experience with 456 combined mitral and aortic valve replacement for rheumatic heart disease[J].Ann Thorac Surg,2000,69:1167-1172.
5.Tominaga R,Kurisu K,Ochiai Y,et al.A 10-year experience with the carbomedics cardiac prosthesis[J].Ann Thorac Surg,2005,79(30:784-789.
6.Cohen G,Borger MA,Weised RD,et al.Intraoperative myocardial protection:current trends and future perspectives[J].Ann Thorac Surg,1999,68:1995-1999.
7.王加利,李佳春,高长青,等.心脏瓣膜置换术中不同心肌灌注方法的研究[J].军医进修学院学报,2003,24(2):152-154.
8.张希,姚尖平,熊迈,等.顺逆行结合灌注冷停搏液对心肌保护的作用[J].中山医科大学学报,2001,22(4):264-266.
9.Sartipy U,Albage A,Lindblom D.The Dor procedure for left ventricular reconstruction.Ten-year clinical experience[J].Eur J Cardiothorac Surg.2005,27(6):1005-10.
10.张春曦,黄达德,伊红.巨大左室二尖瓣机械瓣置换术后远期随访[J].中国心血管病研究杂志.2005,3(2):138-140.
11.于伟勇,张宝仁.联合瓣膜病合并巨大左室的瓣膜替换术[J].上海医学.2000,23(10):599-602.
12.向小勇,李法荫.心脏瓣膜病巨大左室的换瓣治疗经验[J].中国胸心血管外科临床杂志.1996,3(2):88-89.
13.梅举,张宝仁.心脏瓣膜病巨大左室的外科治疗经验[J].中华胸心血管外科杂志.1994,10(4):289-292.
14.Stefanidis C,Nana AM,De Canniere D,et al.10-year experience with the ATS mechanical valve in the mitral position[J].Ann Thorac Surg,2005,79(6):1934-1938.
15.Eery RW,Krogh CC,Arom KV,et al.The St.Jude medical cardiac valve prosthesis:a 25-year experience with single valve replacement[J].Ann Thorac Surg,2005,79(3):776-782.
16.汪曾炜,刘维永,张宝仁.心脏外科学[M]。北京,人民军医出版社,2003,1339-1342。
17.戴小福,陈道中,陈良万,等.巨大左室保留瓣下结构二尖瓣置换术.福建医科大学学报.2004,38(2):203-204.
18.于伟勇,张宝仁,梅举,等.巨大左心室病人心脏瓣膜手术的远期疗效.中华胸心血管外科杂志.2000,16(4):212-214.
19.Zile MR.Chronic aortic and mitral regurgitation:choosing the optimal time for surgical correction.Cardiol Clin.1991,9:239-242.
20.肖颖彬,陈林,王学锋,等.浅低温体外循环心脏跳动中心内直视手术1032例临床分析[J].第三军医大学学报.2001,23(5):502-504.
21.Cohen G,Borger MA,Weised RD,et al.Intraoperative myocardial protection:current trends and future perspectives[J].Ann Thorac Surg.1999,68:1995-1999.
22.Borut Gersaik,Zeijko Sutlic.Aortic and mitral valve surgery on the beating heart is lowering cardiopulmonary bypass and aortic cross clamp time[J].Heart Surg Forum,2002,5(2):182-186.
23.陈柏成,肖颖彬,陈林,等.浅低温体外循环心脏不停跳瓣膜置换术800例临床分析[J].心血管康复医学杂志.2004,13(4):345-348.
24.Toyama M,Usui A,Murayama H,et al.Beating mitral valve replacement for a patient with porcelain aorta[J].Jap J Thorac Cardiovas Surg,2004,52(10):488-490.
25.Amarelli C,Della Corte A,Romano G,et al.Left ventricular mass regression after aortic valve replacement with 17-mm St Jude Medical mechanical prostheses in isolated aortic stenosis[J].J Thorac Cardiovas Surg,2005,129(3):512-517.
26.Penta de Peppo A,Zeitani J,Nardi P,et al.Small "functional" size after mechanical aortic valve replacement:no risk in young to middle-age patients[J].Ann Thorac Surg,2005,79(6):1915-1920.
27.Takahashi T,Hasegawa Y,Ohshima K,et al.Long-term follow-up after aortic valve replacement with a small aortic prosthesis[J].Ann Thorac Cardiovas Surg:Official Journal Of The Association Of Thoracic And Cardiovascular Surgeons Of Asia,2005,11(4):245-248.
28.Paulis RD,Sommariva L,Matteis GMD,et al.Extent and pattern of regression of left ventricular hyertrophy in patients with small size carbomedics aortic valves[J].J Thorac Cardiovasc Surg,1997,113(8):901-909.
29.Paulis RD,Sommariva L,Colagrande L,et al.Regression of left ventricular hypertrophy after aortic valve replacement for aortic stenosis with different valve substitutes[J].J Thorac Cardiovasc Surg,1998,116:590-598.
30.Jose RGJ,Jose MGA,Marino VF,et al.Influence of the size of aortic valve prostheses on hemodynamics and change in left ventricular mass:implications for the surgical management of aortic stenosis[J].J Thorac Cardiovasc Surg,1996,112:273-280.
31.Sawant D,Singh AK,Feng WC,et al.Nineteen millimeter aortic St.Jude medical heart valve prosthesis:up to sixteen years' follow-up[J].Ann Thorac Surg,1997,63:964-970.
32.Kratz JM,Sade RM,Crawford FA,et al.The risk of small St.Jude aortic valve prostheses[J].Ann Thorac Surg,1994,57:1114-1119.
33.Fuster RG,Montero Argudo JA,Albarova OG,et al.Patient-prosthesis mismatch in aortic valve replacement:really tolerable?[J].Eur J Cardio-Thorac Surg,2005,27(3):441-449.
34.Koch CG,Khandwala F,Estafanous FG,et al.Impact of prosthesis-patient size on functional recovery after aortic valve replacement[J].Circ,2005,111(24):3221-3229.
35.Botzenhardt F,Eichinger WB,Bleiziffer S,et al.Hemodynamic comparison of bioprostheses for complete supra-annular position in patients with small aortic annulus of 18 to 20 mm in diameter,J Am Colleg Cardiol.2005,45(2):2054-2060.
36.柳克晔,陈英淳,尤斌,等.重症风湿性心脏病瓣膜关闭不全的围术期处理[J].中华胸心血管外科杂志.2003,19(1):25-28.
37.张宝仁.二尖瓣和主动脉瓣置换手术.见:张宝仁,朱家麟,主编.人造心脏瓣膜与瓣膜置换术(第二版).北京:人民卫生出版社,1999.353.
38.Sire EKW,O rszulak TA,Schaff HV,et al.Influence of prosthesis size on change in left ventricular mass following aortic valve replacement[J].Eur J Cardio thorac Surg.1994,8(6):293-298.
39.Gonzalez-Juanatey JR,Garcia-Acuna JM,Vega-Fernandez M,et al.Influence of the size of aortic valve prostheses on hemodynamics and change in left ventricular mass:implications for the surgical management of aortic stenosis[J].J Thorac Cardiovasc Surg.1996,12(2):273-281.
40.Villari B,Vassalli G,Monrad ES,et al.Nor malization of diastolic dysfunction in aortic stenosis late after valve replacement[J].Circ,1995,91(9):2353-2359.
41.Gonzalez Juanaey JR,Garcia Acuna JM,Vega Fernandez M,et al.Influence of the size of aortic valve prosthese on hemodynamics and change in left ventricular mass:implication for the surgical management of aortic stenosis[J].J Thorac Cardiovasc Surg,1996,112(2):273-280.
42.Gjertsson,Peter;Caidahl,Kenneth;Bech-Hanssen,Odd.Left ventricular diastolic dysfunction late after aortic valve replacement in patients with aortic stenosis[J].American J Cardiol,2005,96(5):722-727.
43.Okuyama H,Hashimoto K,Kurosawa H,et al.Midterm results of Manouguian double valve replacement:comparison with standard double valve replacement[J].J Thorac Cardiovas Surg,2005,129(4):869-874.
44.万亚红,张光休,程可洛,等.双瓣膜置换术中人工瓣膜的匹配[J].中国胸心血管外科临床杂志.2000,7(1):57-58.
45.许传青,徐小虎,于晓军,等.心瓣膜置换术远期死亡因素的Logistic回归模型与分析[J].北京生物医学工程.2005,24(1):13-15.
46.陈林,肖颖彬,王学锋,等.合并巨大左心房室瓣膜病的外科治疗[J].中华外科杂志.2004,42(4):252-253.
47.Tonguc E,Kestelli M,Ozsoyler I,et al.Reversible airway obstruction in rheumatic mitral valve disease[J].Respirology,1998,3(1):25-31.
48.Shenkman Z,Shir Y,Weiss YG,et al.The effects of cardiac surgery on early and late pulmonary functions[J].Acta Anaesthesiol Scand,1997,41(10):1193-1199.
49.Chandra A,Srivastava S,Dilip D.Spirometric changes following open-heart surgery on rheumatic mitral valves[J].Asian Cardiovasc Thorac Ann 1998,6(1):28-33.
50.Polese G,Lubli P,Mazzucco A,et al.Effects of open heart surgery on respiratory mechanical[J].Intensive Care Med,1999,25(10):1092-1099.
51.左景珍,于昂,李卫民,等.702例心脏瓣膜置换术及其主要并发症的临床分析[J].中华外科杂志.2002,40(5):354-356.
52.Rho RW,Bridges CR,Kocovic D.Management of postoperative arrhythmias[J].Seminars in Thorac Cardiovasr Surg,2000,12:349-361.
53.Vaquette B,Corbineau H,Laurent M;et al.Valve replacement in patients with critical aortic stenosis and depressed left ventricular function:predictors of operative risk,left ventricular function recovery,and long term outcome[J].Heart,2005,91(10):1324-1329.
54.Taylor Nyali E,O'Brien Sean,Edwards Fred H,et al.Relationship between race and mortality and morbidity after valve replacement surgery[J].Circ,2005,111(10):1305-1312.
55.赵康丽,虞敏,刘楠,等.心脏外科直视术后心律失常的发生率及其风险因素分析[J].中华心律失常学杂志.2004,8(6):375-376.
56.陈林,肖颖彬,钟前进,等.心内直视手术后多脏器功能衰竭的危险因素与防治措施[J].中国急救医学,2004,24(2):81-83.
57.Combes A,Troullet JL,Baudot J,et al.Is it possible to cure mediastinitis in patients with major postcardiac surgery complication[J].Ann Thorac Surg,2001,72(5):1592-1597.
58.Rahimtoola SH.The problem of valve prosthesis-patient mismatch[J].Circ,1978,58(1):20-24.
59.Pibarot P,Dumesnil JG,Cartier PC,et al.Patient-prosthesis mismatch can be predicted at the time of operation[J].Ann Thorac Surg,2001,71(5):964-970.
60.Kawada N,Tanaka K.Nicks operation for aortic valve dysfunction with pannus formation;report of a case[J].Jap J Thoracc Surg,2005,58(10):929-933.
61.De Oliveira,NC,David TE,Armstrong S.Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body:an analysis of clinical outcomes[J].J Thorac Cardiovas Surg,2005,129(2):286-290.
62.Castro LJ,Arcidi JMJ,Fisher AL et al.Routine enlargement of the small aortic root:a preventive strategy to minimize mismatch[J].Ann Thorac Surg,2002,74(1):31-36.
63.Rao V,Jamieson WR,Ivanov J,et al.Prosthesis-patient mismatch affects survival after aortic valve replacement[J].Circ,2000,102(9 Supplement 3):Ⅲ5-Ⅲ9.
64.Arom KV,Goldenberg IF and Emery RW.Long-term clinical outcome with small size standard St.Jude Medical valves implanted in the aortic position[J].J Heart Valve Dis,1994,3(5):531-536.
65.Medalion B,Blackstone EH,Lytle BW,et al.Aortic valve replacement:is valve size important? [J]. J Thorac Cardiovas Surg, 2000,119(5): 963-974.
66. Freed DH, Tarn JW, Moon MC, et al. Nineteen-millimeter prosthetic aortic valves allow normalization of left ventricular mass in elderly women [J]. Ann Thorac Surg, 2002, 74(6):2022-2025.
67. Yamasaki M, Sasaguri S, Hosoda Y, et al.Long-term results for aortic valve replacement with small aortic annulus [J]. Artificial Organs, 2002, 26(5): 474-478.
68. Hanayama N, Cristakis GT, Mallidi HR, et al. Patient prosthesis mismatch is rare after aortic valve replacement: valve size may be irrelevant [J]. Ann Thorac Surg, 2002,73(6): 1056-1062.
69. Takai H, Yamachika S,Hazama S,et al. Consideration of prosthesis-patient mismatch and left ventricular mass regression after implantation of the Carpentier-Edwards perdicardial valve in elderly Japanese patients: body surface area may be irrelevant [J]. J Artificial Organs,2004,7(4):203-206.
70. Ismeno G, Renzulli A, De Feo M, et al. Standard versus hemodynamic plus 19-mm St Jude Medical aortic valves [J]. J Thorac Cardiovasc Surg, 2001,121(5): 723-728.
71. He GW, Grunkemeier GL, Gately HL, et al. Up to thirty-year survival after aortic valve replacement in the small aortic root [J]. Ann Thorac Surg, 1995,59(5):1056-1062.
72. Knez I, Rienmuller R, Maier R, et al. Left ventricular architecture after valve replacement due to critical aortic stenosis: an approach to dis-/qualify the myth of valve prosthesis-patient mismatch? [J]. Eur J Cardio-Thorac Surg, 2001, 19(6): 797-805.
73. Ennker J, Rosendahl U, Albert A. Stentless bioprostheses in small aortic roots: impact of patient-prosthesis mismatch on survival and quality of life [J]. J Heart Valve Dis, 2005, 14(4): 523-530.
74. Milano AD, Carlo MD,Mecozzi G,et al. Clinical outcome in patients with 19-mm and 21-mm St. Jude aortic prostheses: comparison at long-term follow-up [J]. Ann Thorac Surg,2002,73(1):37-43.
75. Kaiser SP, Melby SJ, Zierer A, et al. Long-term outcomes in valve replacement surgery for infective endocarditis. [J]. Ann-Thorac-Surg. 2007. 83(1): 30-5.
76. Athanasuleas C, Siler W, Buckberg G. Myocardial protection during surgical ventricular restoration. Eur J Cardiothorac Surg. 2006, Suppl 1: S231-7.
77. Ramires FJ, Salemi VM, Ianni BM, et al. Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. J Renin Angiotensin Aldosterone Syst. 2006, 7(3): 162-7.
78. Savini C, Camurri N, Castelli A. Myocardial protection using HTK solution in minimally invasive mitral valve surgery. Heart Surg Forum. 2005, 8(1): E25-7.
79. Fischer UM, Cox CS, Laine GA, et al. Mild hypothermia impairs left ventricular diastolic but not systolic function. J Invest Surg. 2005, 18(6): 291-6.
80. Nemes A, Galema TW, Geleijnse ML, et al. Aortic valve replacement for aortic stenosis is associated with improved aortic distensibility at long-term follow-up. Am Heart J. 2007, 153(1): 147-51.
81. Chowdhury UK, Venkataiya JK, Patel CD. Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease. Am Heart J. 2006, 152(6): 1201-7.
82. Cicekcioglu F, Tutun U, Babaroglu S, et al. Beating heart mitral valve replacement with retrograde coronary sinus perfusion technique. J Cardiovasc Surg (Torino). 2006, 47(5): 575-9.
83. Khan SS, Siegel RJ, DeRobertis MA, et al. Regression of hypertrophy after Carpentier-Edwards pericardial aortic valve replacement [J]. Ann Thorac Surg, 2000, 69(2):531-535.
84. Arata KI, Iguro Y, Masuda H, et al. Long-term follow up in patients receiving a small aortic valve prosthesis [J]. J Heart Valve Dis, 2002,11(6):780-784.
85. Natsuaki M, TohT, Okazaki Y, et al. Influence of St. Jude medical valve in patients with aortic stenosis and small aortic annulus on cardiac function and late survival result [J]. Artificial Organs, 2002,26,(10):840-846.
86. Stike PC,Edwards TJ,Stevan DG,et al.Functional hemodynamic assessment of the 21-mm and 23-mm CarboMedics Top Hat prosthetic valve[J].J Card Surg, 1998, 13(1):98-103.
87. Caus T,Rouviere P,Collart F,et al.late of double-valve replacement wuth biologic or mechanical prostheses [J]. Ann Thorac Surg,2001,71(5 supple 1): s261-s264.
88. Banerjee P,Clark AL,Cleland GF, et al. Diastolic heart failure: a difficult problem in elderly [J]. AM J Geriater Cardiol,2004,13(1): 16-21.
89. Khan S,Bess RL,Rosman HS, et al. Which echocaodiographic Doppler left ventricular diastolic function measurement are most feasible in the clinical echocardiographic laboratory[J].AM J Cardiol,2004,94(8):1099-1101.
90.Talwalkar NG,Lawrie GM,Earle N,et al.Can retrograde cardioplegia alone provide adequate protection for cardiac valve surgery[J].Chest,1999,115:135-139.
91.Tian G,Xiang B,Dai G,et al.The effects of retrograde cardioplegic technique on mgocardial perfusion and energe metabolism[J].Thorac Cardiovasc surg,2000,120(3):544-551.
92.黄元鲁.冠状动脉顺心行灌注心脏不停跳主动脉瓣置换术的心肌保护[J].广西医科大学学报.2004,21(1):82-83.
93.Chocron S,Kalli D,Yunsheng Y,et al.Intermediate warm antegrade intermittent blood cardioplegia compared with cold and warm blood cardioplegia[J].J Thorac Cardiovasc Surg,2000,119(3):610-616.
94.Lajos TI,Esperson EC,Lajos PC,et al.Comparison of cold with warm cardioplegia crystalloid antegrade or retrograde blood[J].Circulation,1993,88(2):344-349.
95.Rueng SP,Buxton BF.Anatomic and hemodynamic considerations influencing the efficiency of retrograde cardioplegia[J].Ann Thorac Surg,2001,71(4):1389-1395.
96.Hirata N,Sakai K,Oh TM,et al.Assessment of myocardial distribution of retrograde and antegrade cardiop legik solution in the same patients[J].Eur J Cardiothorac Surg,1997,12(2):242-247.
97.Arom KV,Emery RW,Petersen RJ,et al.Evalution of 7000+ patients with two different routes of cardioplegia[J].Ann Thorac Surg,1997,63(6):1619-1624.
98.Tian G,Xiang B,Dai G,et al.Retrograde cardioplegia[J].J Thorac Cardiovasc Surg,2003,125(4):872-880.
99.Carrier M,Leung TK,Solymoss BC,et al.Clinical trial of retrograde warm blood reperfusion versus standard cold topical irrigation of transplanted hearts[J].Ann Thorac Surg,1996,61(5):1310-1315.
100.Tehrani H,Masroor S,Lombardi P,et al.Beating heart aortic valve replacement in a pregnant patient[J].J Cardiac Surg,2004,19(1):57-58.
101.潘柏申.心脏标志物的临床应用[J].中华检验医学杂志,2005,28(1):124-126.
102.Micheli A,Chavez E.Ischemia-reperfusion myocardial injury.Arch Cardiolog,2003,73(4):284-290.
103.Kuznetsov AV,Schneeberger S,Seiler RBG et al.Mitochondrial defects and heterogeneous cytochrome c release after cardiac cold ischemia and reperfusion[J].AM J Physiol(Heart Circ Physiol),2004,286(5):H1633-H1641.
104.Bodor GS,Survant L,Voss EM,et al.Cardiac troponin T composition in normal and regenerating human skeletal muscle[J].Clin Chem,1997,43(3):476-84.
105.Hirsch R,Dent CL,Wood MK,et al.Patterns and potential value of cardiac troponin Ielevations after pediatric cardiac operations[J].Ann Thorac Surg,1998,65(5):1394-1399.
106.Cook DJ.Changing temperature management for cardiopulmonary bypass[J].Anesth Analg,1999,88:1254-1271.
107.Piper HM,Dorado GD,Ovize M,et al.A fresh look at reperfusion injury[J].Cardiovasc Res,1998,38(3):291-300.
108.周骐,肖颖彬,陈林.逆灌浅低温氧合血心脏不停跳和冷血心脏麻痹液对心肌代谢影响的临床研究[J].创伤外科杂志,2003,5(2):114-117.
109.Levy JH,Tanaka KA.Inflammatory response to cardiopulmonary bypass[J].Ann Thorac Surg,2003,75(2):S715-20.
110.Munoz R,Laussen PC,Palacio G,et al.Changes in whole blood lactate levels during cardiopulmonary bypass for surgery for congenital cardiac disease:an early indicator of morbidity and moetality.J Thorac Cardiovasc Surg,2000;119:155-162
111.Hashimoto K,Sasaki T,Hachiya T,et al.Influence of cardiopulmonary bypass temperature on circulatory pathophysiology and clinical outcomes[J].Jpn Circ J,2000,64(4):436-444.
112.Lehman JJ,Kelly DP.Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart[J].Clin Exp Pharmacol Physiol,2002,29(4):339-345.
113.Casademont J,Miro O.Electron transport chain defects in heart failure[J].Heart Fail Rev,2002,7(2):131-139.
114.Recchia FA,Mcconnell PI,Bernstein RD,et al.Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog[J].Circ Res,1998,83(10):969-979.
115.Razeghi P,Young ME,Alcorn JL,et al.Metabolic gene expression in fetal and failing human heart [J]. Circulation,2001,104(24):2923-2931.
116. Rosenblatt VN, Montessuit C, Papageorgiou I,et al. Post infarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism [J]. Cardiovasc Res, 2001,52(3):407-416.
117. Liu Q, Docherty JC,Rendell JCT, et al. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation [J]. J Am Coll Cardiol,2002,39(4):718-725.
118. Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial infarcts. Ann Review Biomed Engineer, 2005,7(2): 223-253.
119. Brasselet C, Durand E, Addad F, et al.Collagen and elastin cross-linking: a mechanism of constrictive remodeling after arterial injury [J].AM J Physio(Heart And Circ Physiol), 2005,289(5): H2228-H2233.
1.张宝仁,邹良建,徐志云,等.风湿性瓣膜病二尖瓣与主动脉瓣置换术1154例长期效果分析[J].中华外科杂志,2003,41(4):243-246.
2.张春曦,黄达德,伊红.巨大左室二尖瓣机械瓣置换术后远期随访[J].中国心血管病研究杂志.2005,3(2):138-140.
3.李军,杨康,杨军民,等.合并巨大左室的重症风湿性瓣膜病的外科治疗[J].重庆医学.2004,33(12):1788-1789.
4.于伟勇,张宝仁.联合瓣膜病合并巨大左室的瓣膜替换术[J].上海医学.2000,23(10):599-602.
5.向小勇,李法荫.心脏瓣膜病巨大左室的换瓣治疗经验[J].中国胸心血管外科临床杂志.1996,3(2):88-89.
6.梅举,张宝仁.心脏瓣膜病巨大左室的外科治疗经验[J].中华胸心血管外科杂志.1994,10(4):289-292.
7.Klodas E,sarano ME,Tajik AJ,et al.Arotic regurgitation complicated by extreme left ventricular dilation:long term outcome after surgical correction[J].J Am Coll Cardiol,1996,27(3):670-677.
8.Miller,-G-L.Aortic regurgitation with extreme left ventricular dilation.J Am Coll Cardiol.1996,28(3):798-9.
9.徐志云,张宝仁,朱家麟,等.风心病二尖瓣狭窄合并小左室的瓣膜替换术经验[J].中华胸心血管外科杂志,1997,13(1):1-4.
10.Krayenbuehl HP,Hess O,Monrad ES,et al.Left ventricular myocardial structure in aortic valve disease before intermediate and late after aortic valve replacement[J].Circulation,1989,79(4):744-755.
11.Spinale FG,Ishihra K,Zile M,et al.Structural basis for changes in left ventricular function and geometry because of chronic mitral regurgitation and after correction of volume overload[J].J Thorac Cardiovasc Surg,1993,106(6):1147-1157.
12.Roman MJ,Klein L,Devereux RB,et al.Reversal of left ventricular dilation hypertrophy,and dysfunction by valve replacement in aortic regurgitation[J].Am Heart J,1989,118(3):553-563.
13.Bonow RO,Dott J T,Maron BJ,et al.Long term serial change in left ventricular function and reversal of ventricular dilation after valve replacement for chronic aortic regurgitation[J].Circulation,1988,78(5):1108-1120.
14.Pela G,La Ganna G,Metra M.Long-term changes in left ventricular mass,chamber size and function after valve replacement in patient and sever aortic stenosis and depressed ejection fraction[J].Cardiology,1997,88(4):315-322.
15.Enriquez Sarano M,Tajik AJ,Schaff HV,et al.Echocardiographic prediction of left ventricular function after correction of mitral regurgitation,results and clinical implication[J].J Am Coll Cardiol,1994,24(6):1536-1543.
16.陈勇兵,顾泗荣,王岩,等.小左室二尖瓣的替换术的围手术期的处理[J].中华胸心血管外科杂志,1996,16(4):703-704.
17.沈家宜,严志琨,徐海林,等.巨大左心室的瓣膜病的外科治疗[J].中华胸心血管外科杂志,1999,15(2):72-74.
18.Ren J F,Ksut S,Lighty GW,et al.Mitral valve repair is superior to valve replacement for the early preservation of cardiac function:relation of ventricular geometry to function[J].Am Heart J,1996,131(5):974-981.
19.沈家宜,严志琨,孔颂阳,等.巨大心脏瓣膜替换术围手术期处理[J].上海医学,1996,19(11):631-633.
20.潘晓鸣,薛武军,田普训,等.营养支持在肾移植围手术期的应用.西安交通大学学报:医学版.2007,28(1):97-99.
21.李宁.围手术期营养支持.临床外科杂志.2006,14(9):544-545.
22.黎介寿.围手术营养支持的需要性.肠外与肠内营养.2006,13(3):129-131.
1.Murry CE,Jennings RB,Reimer KA.Preconditioning with ischemia:a delay of lethal cell injury in ischemic myocardium.Circulation,1986,74(5):1124-1136.
2.Marber MS,Latchman DS,Walker JM,et al.Cardiac stress protein elevation 24hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.Circulation,1993,88(3):1264-1272.
3.Barbosa V,Sievers RE,Zaugg CE,et al.Preconditioning ischemia time determines the degree of glycogen depletion and infarct size reduction in rat heart.Am.Heart J.1996,131:224-230.
4.Piot CA,Padmanaban D,Ursell PC,et al.Ischemic preconditioning decreases apoptosis in rat hearts in vivo.Circulation.1997,96:1598-1604.
5.Iliodromitis EK,Kremastinos DT,Katritsis DG,et al.Multiple cycles of preconditioning cause loss of protection in open-chest rabbits.J.Mol.Cell Cadiol.1997,29:915-920.
6.Verdouw PD,Gho BC,Koning MM,et al.Cardioprotection by ischemic and nonischemic myocardial stress and ischemia in remote organs:Implications for the concept of ischemic preconditioning.Ann.N.Y.Acad.Sci.1996,793:27-42.
7.Birnbaum Y,Hale SL,Kloner RA.Ischemic preconditioning at distance:reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit.Circulation.1997,96:1641-1646.
8.Yellon DM,Alkhulaifi AM,Pugsley WB.Preconditioning the human myocardium[J].Lancet,1993,342:276-277.
9.Wu ZK,Tarkka MR,Eloranta J,et al.Effect of ischemic preconditioning on myocardial protection in coronary artery bypass graft patients:can the free radicals act as a trigger for ischemic preconditioning? Chest.2001;119(4):1061-8.
10.Li G,Chen S,Lu E,et al.Ischemic preconditioning improves preservation with cold blood cardioplegia in valve replacement patients.Eur.J.Cardiothorac.Surg.1999;15(5):653-7.
11.姚尖平,张希,吴钟凯等.缺血预处理在心瓣膜置换术中对心肌保护的作用.中国胸心血管外科临床杂志 2006,13(5):311-314.
12. Gunaydin B, Cakici I, Soncul H, et al. Does remote organ ischemia trigger cardiac preconditioning during coronary artery surgery? Pharmacol. Res. 2000, 41:493-496.
13. Kitakaxe M, Hori M. Ischemic preconditioning increase adenosine release and 5'-nucleotidase activity during myocardial ischemic and reperfusion in dogs implication for myocardial salvage. Circulation, 1993, 87: 208-215.
14. Jason N. Peart and John P. Headrick Adenosinergic cardioprotection: Multiple receptors, multiple pathways. Pharmacology & Therapeutics, 2007.
15. Ahmet I, Sawa Y, Nishimura M, et al. Myocardial protection using diadenosine tetraphosphate with pharmacological preconditioning. Ann Thorac Surg , 2000 , 70 (3): 901-905.
16. McCully JD, Uematsu M, Parker RA, et al. Adenosine-enhanced ischemic preconditioning provides enhanced cardioprotection in aged heart. Ann Thorac Surg, 1998,66:2037-2043.
17. Mehta AB, Mardikar HM, Hiregouder NS, et al. Preconditioning the human myocardium with intracoronary adenosine. Indian Hear J, 1998, 50: 397-401.
18. Noma A. ATP-regulated K~+ channels in cardiacmuscle. Nature, 1983;305:147-148.
19. Inoue I, Nagase H, Kishi K, et al. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature, 1991, 352:244-247.
20. Wang X, Wei M, Kuukasjarvi P. Novel pharmacological preconditioning with diazoxide attenuates myocardial stunning in coronary artery bypass grafting. Eur J Cardiothorac Surg. 2003; 24(6): 967-73.
21. Sanada S, Kitakaze M, Asanuma H, et al. Role of mitochondria and sarcolemmal K(ATP)channels in ischemic preconditioning of the canine heart. Am J Physiol Heart Circ Physiol, 2001 280:256-263.
22. Tsuchida A, Miura T, Tanno M, et al. Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemma K(ATP) channels, and protein kinaseC. J Am Coll Cardiol 2002, 40: 1523-1530.
23. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol, 2000, 35: 345-351.
24. Sharony R, Frolkis I, Froylich D. Pharmacological preconditioning with monophosphoryl lipid A improves post ischemic diastolic function and modifies TNF-alpha synthesis. Eur J Cardiothorac Surg. 2005; 27(3): 501-7.
25. Yoshida T, Engelman RM, Engelman DT. Preconditioning of swine heart with monophosphoryl lipid A improves myocardial preservation. Ann Thorac Surg. 2000; 70(3): 895-900.
26. Gyorgy K, Muller B, Vegh A, et al. Triggering role of nitric oxide in the delayed protective effect of monophosphoryl lipid A in rat heart. Br Pharmacol, 1999, 127: 1892-1898.
27. Kehl F, Pagel PS, Krolikowski JG, et al. Is isoflurane-induced preconditioning dose elated. Anesthesiol, 2002, 96(3): 675-680.
28. Li F, Hayes JK, Wong KC, et al. Administration of sevoflurane and isoflurane prior to prolonged global ischemia improves heart function in isolated rat heart. Acta Anaesthesiologica Sinica, 2000, 38(1):113-121.
29. Belhomme D, Peynet J, Lounay JM, et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation, 1999, 100: 340-344.
30. Katsuya T, Lynda M, Ludwig BS, et al. Mechanisms of cardio-protection by volatile anesthetics. Anesthesiology, 2004, 100: 707-721.
31. Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide- sensitive mechanism in the rat heart. Circ Res 1996;78:110-4.
32. Karck M, Tanaka S, Boiling SF, Simon A, Tsung-Ping Su, Oeltgen PR, Haverich A. Myocardial protection by ischemic preconditioning and d-opioid receptor activation in the isolated working rat heart. J Thorac Cardiovasc Surg 2001;122:986-92.
33. Feng J, Li H, Rosenkranz ER. Bradykinin protects the rabbit heart after cardioplegic ischemia via NO-dependent pathways. Ann Thorac Surg. 2000; 70(6): 2119-24.
34. Tom B, Dendorfer A, Danser AH, et al. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int. J. Biochem. Cell Biol. 2003,35: 792-801.
35. Schwarz ER, Montino H, Fleischhauer J, et al. Angiotensin II receptor antagonist EXP3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc. Drugs Ther. 1997, 11:687-695.
36. Miki T, Miura T, Ura N, et al. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. J. Am. Coll. Cardiol. 1996,28:1616-1622.
2.张宝仁,邹良建,徐志云,等.风湿性瓣膜病二尖瓣与主动脉瓣置换术1154例长期效果分析[J].中华外科杂志,2003,41(4):243-246.
3.Kang CH,Ahn H,Kim KH.Long-term result of 1144 CarboMedics mechanical valve implantations[J].Ann Thorac Surg,2005,79(6):1939-1944.
4.John S,Ravikumar E,John CN,et al.25-year experience with 456 combined mitral and aortic valve replacement for rheumatic heart disease[J].Ann Thorac Surg,2000,69:1167-1172.
5.Tominaga R,Kurisu K,Ochiai Y,et al.A 10-year experience with the carbomedics cardiac prosthesis[J].Ann Thorac Surg,2005,79(30:784-789.
6.Cohen G,Borger MA,Weised RD,et al.Intraoperative myocardial protection:current trends and future perspectives[J].Ann Thorac Surg,1999,68:1995-1999.
7.王加利,李佳春,高长青,等.心脏瓣膜置换术中不同心肌灌注方法的研究[J].军医进修学院学报,2003,24(2):152-154.
8.张希,姚尖平,熊迈,等.顺逆行结合灌注冷停搏液对心肌保护的作用[J].中山医科大学学报,2001,22(4):264-266.
9.Sartipy U,Albage A,Lindblom D.The Dor procedure for left ventricular reconstruction.Ten-year clinical experience[J].Eur J Cardiothorac Surg.2005,27(6):1005-10.
10.张春曦,黄达德,伊红.巨大左室二尖瓣机械瓣置换术后远期随访[J].中国心血管病研究杂志.2005,3(2):138-140.
11.于伟勇,张宝仁.联合瓣膜病合并巨大左室的瓣膜替换术[J].上海医学.2000,23(10):599-602.
12.向小勇,李法荫.心脏瓣膜病巨大左室的换瓣治疗经验[J].中国胸心血管外科临床杂志.1996,3(2):88-89.
13.梅举,张宝仁.心脏瓣膜病巨大左室的外科治疗经验[J].中华胸心血管外科杂志.1994,10(4):289-292.
14.Stefanidis C,Nana AM,De Canniere D,et al.10-year experience with the ATS mechanical valve in the mitral position[J].Ann Thorac Surg,2005,79(6):1934-1938.
15.Eery RW,Krogh CC,Arom KV,et al.The St.Jude medical cardiac valve prosthesis:a 25-year experience with single valve replacement[J].Ann Thorac Surg,2005,79(3):776-782.
16.汪曾炜,刘维永,张宝仁.心脏外科学[M]。北京,人民军医出版社,2003,1339-1342。
17.戴小福,陈道中,陈良万,等.巨大左室保留瓣下结构二尖瓣置换术.福建医科大学学报.2004,38(2):203-204.
18.于伟勇,张宝仁,梅举,等.巨大左心室病人心脏瓣膜手术的远期疗效.中华胸心血管外科杂志.2000,16(4):212-214.
19.Zile MR.Chronic aortic and mitral regurgitation:choosing the optimal time for surgical correction.Cardiol Clin.1991,9:239-242.
20.肖颖彬,陈林,王学锋,等.浅低温体外循环心脏跳动中心内直视手术1032例临床分析[J].第三军医大学学报.2001,23(5):502-504.
21.Cohen G,Borger MA,Weised RD,et al.Intraoperative myocardial protection:current trends and future perspectives[J].Ann Thorac Surg.1999,68:1995-1999.
22.Borut Gersaik,Zeijko Sutlic.Aortic and mitral valve surgery on the beating heart is lowering cardiopulmonary bypass and aortic cross clamp time[J].Heart Surg Forum,2002,5(2):182-186.
23.陈柏成,肖颖彬,陈林,等.浅低温体外循环心脏不停跳瓣膜置换术800例临床分析[J].心血管康复医学杂志.2004,13(4):345-348.
24.Toyama M,Usui A,Murayama H,et al.Beating mitral valve replacement for a patient with porcelain aorta[J].Jap J Thorac Cardiovas Surg,2004,52(10):488-490.
25.Amarelli C,Della Corte A,Romano G,et al.Left ventricular mass regression after aortic valve replacement with 17-mm St Jude Medical mechanical prostheses in isolated aortic stenosis[J].J Thorac Cardiovas Surg,2005,129(3):512-517.
26.Penta de Peppo A,Zeitani J,Nardi P,et al.Small "functional" size after mechanical aortic valve replacement:no risk in young to middle-age patients[J].Ann Thorac Surg,2005,79(6):1915-1920.
27.Takahashi T,Hasegawa Y,Ohshima K,et al.Long-term follow-up after aortic valve replacement with a small aortic prosthesis[J].Ann Thorac Cardiovas Surg:Official Journal Of The Association Of Thoracic And Cardiovascular Surgeons Of Asia,2005,11(4):245-248.
28.Paulis RD,Sommariva L,Matteis GMD,et al.Extent and pattern of regression of left ventricular hyertrophy in patients with small size carbomedics aortic valves[J].J Thorac Cardiovasc Surg,1997,113(8):901-909.
29.Paulis RD,Sommariva L,Colagrande L,et al.Regression of left ventricular hypertrophy after aortic valve replacement for aortic stenosis with different valve substitutes[J].J Thorac Cardiovasc Surg,1998,116:590-598.
30.Jose RGJ,Jose MGA,Marino VF,et al.Influence of the size of aortic valve prostheses on hemodynamics and change in left ventricular mass:implications for the surgical management of aortic stenosis[J].J Thorac Cardiovasc Surg,1996,112:273-280.
31.Sawant D,Singh AK,Feng WC,et al.Nineteen millimeter aortic St.Jude medical heart valve prosthesis:up to sixteen years' follow-up[J].Ann Thorac Surg,1997,63:964-970.
32.Kratz JM,Sade RM,Crawford FA,et al.The risk of small St.Jude aortic valve prostheses[J].Ann Thorac Surg,1994,57:1114-1119.
33.Fuster RG,Montero Argudo JA,Albarova OG,et al.Patient-prosthesis mismatch in aortic valve replacement:really tolerable?[J].Eur J Cardio-Thorac Surg,2005,27(3):441-449.
34.Koch CG,Khandwala F,Estafanous FG,et al.Impact of prosthesis-patient size on functional recovery after aortic valve replacement[J].Circ,2005,111(24):3221-3229.
35.Botzenhardt F,Eichinger WB,Bleiziffer S,et al.Hemodynamic comparison of bioprostheses for complete supra-annular position in patients with small aortic annulus of 18 to 20 mm in diameter,J Am Colleg Cardiol.2005,45(2):2054-2060.
36.柳克晔,陈英淳,尤斌,等.重症风湿性心脏病瓣膜关闭不全的围术期处理[J].中华胸心血管外科杂志.2003,19(1):25-28.
37.张宝仁.二尖瓣和主动脉瓣置换手术.见:张宝仁,朱家麟,主编.人造心脏瓣膜与瓣膜置换术(第二版).北京:人民卫生出版社,1999.353.
38.Sire EKW,O rszulak TA,Schaff HV,et al.Influence of prosthesis size on change in left ventricular mass following aortic valve replacement[J].Eur J Cardio thorac Surg.1994,8(6):293-298.
39.Gonzalez-Juanatey JR,Garcia-Acuna JM,Vega-Fernandez M,et al.Influence of the size of aortic valve prostheses on hemodynamics and change in left ventricular mass:implications for the surgical management of aortic stenosis[J].J Thorac Cardiovasc Surg.1996,12(2):273-281.
40.Villari B,Vassalli G,Monrad ES,et al.Nor malization of diastolic dysfunction in aortic stenosis late after valve replacement[J].Circ,1995,91(9):2353-2359.
41.Gonzalez Juanaey JR,Garcia Acuna JM,Vega Fernandez M,et al.Influence of the size of aortic valve prosthese on hemodynamics and change in left ventricular mass:implication for the surgical management of aortic stenosis[J].J Thorac Cardiovasc Surg,1996,112(2):273-280.
42.Gjertsson,Peter;Caidahl,Kenneth;Bech-Hanssen,Odd.Left ventricular diastolic dysfunction late after aortic valve replacement in patients with aortic stenosis[J].American J Cardiol,2005,96(5):722-727.
43.Okuyama H,Hashimoto K,Kurosawa H,et al.Midterm results of Manouguian double valve replacement:comparison with standard double valve replacement[J].J Thorac Cardiovas Surg,2005,129(4):869-874.
44.万亚红,张光休,程可洛,等.双瓣膜置换术中人工瓣膜的匹配[J].中国胸心血管外科临床杂志.2000,7(1):57-58.
45.许传青,徐小虎,于晓军,等.心瓣膜置换术远期死亡因素的Logistic回归模型与分析[J].北京生物医学工程.2005,24(1):13-15.
46.陈林,肖颖彬,王学锋,等.合并巨大左心房室瓣膜病的外科治疗[J].中华外科杂志.2004,42(4):252-253.
47.Tonguc E,Kestelli M,Ozsoyler I,et al.Reversible airway obstruction in rheumatic mitral valve disease[J].Respirology,1998,3(1):25-31.
48.Shenkman Z,Shir Y,Weiss YG,et al.The effects of cardiac surgery on early and late pulmonary functions[J].Acta Anaesthesiol Scand,1997,41(10):1193-1199.
49.Chandra A,Srivastava S,Dilip D.Spirometric changes following open-heart surgery on rheumatic mitral valves[J].Asian Cardiovasc Thorac Ann 1998,6(1):28-33.
50.Polese G,Lubli P,Mazzucco A,et al.Effects of open heart surgery on respiratory mechanical[J].Intensive Care Med,1999,25(10):1092-1099.
51.左景珍,于昂,李卫民,等.702例心脏瓣膜置换术及其主要并发症的临床分析[J].中华外科杂志.2002,40(5):354-356.
52.Rho RW,Bridges CR,Kocovic D.Management of postoperative arrhythmias[J].Seminars in Thorac Cardiovasr Surg,2000,12:349-361.
53.Vaquette B,Corbineau H,Laurent M;et al.Valve replacement in patients with critical aortic stenosis and depressed left ventricular function:predictors of operative risk,left ventricular function recovery,and long term outcome[J].Heart,2005,91(10):1324-1329.
54.Taylor Nyali E,O'Brien Sean,Edwards Fred H,et al.Relationship between race and mortality and morbidity after valve replacement surgery[J].Circ,2005,111(10):1305-1312.
55.赵康丽,虞敏,刘楠,等.心脏外科直视术后心律失常的发生率及其风险因素分析[J].中华心律失常学杂志.2004,8(6):375-376.
56.陈林,肖颖彬,钟前进,等.心内直视手术后多脏器功能衰竭的危险因素与防治措施[J].中国急救医学,2004,24(2):81-83.
57.Combes A,Troullet JL,Baudot J,et al.Is it possible to cure mediastinitis in patients with major postcardiac surgery complication[J].Ann Thorac Surg,2001,72(5):1592-1597.
58.Rahimtoola SH.The problem of valve prosthesis-patient mismatch[J].Circ,1978,58(1):20-24.
59.Pibarot P,Dumesnil JG,Cartier PC,et al.Patient-prosthesis mismatch can be predicted at the time of operation[J].Ann Thorac Surg,2001,71(5):964-970.
60.Kawada N,Tanaka K.Nicks operation for aortic valve dysfunction with pannus formation;report of a case[J].Jap J Thoracc Surg,2005,58(10):929-933.
61.De Oliveira,NC,David TE,Armstrong S.Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body:an analysis of clinical outcomes[J].J Thorac Cardiovas Surg,2005,129(2):286-290.
62.Castro LJ,Arcidi JMJ,Fisher AL et al.Routine enlargement of the small aortic root:a preventive strategy to minimize mismatch[J].Ann Thorac Surg,2002,74(1):31-36.
63.Rao V,Jamieson WR,Ivanov J,et al.Prosthesis-patient mismatch affects survival after aortic valve replacement[J].Circ,2000,102(9 Supplement 3):Ⅲ5-Ⅲ9.
64.Arom KV,Goldenberg IF and Emery RW.Long-term clinical outcome with small size standard St.Jude Medical valves implanted in the aortic position[J].J Heart Valve Dis,1994,3(5):531-536.
65.Medalion B,Blackstone EH,Lytle BW,et al.Aortic valve replacement:is valve size important? [J]. J Thorac Cardiovas Surg, 2000,119(5): 963-974.
66. Freed DH, Tarn JW, Moon MC, et al. Nineteen-millimeter prosthetic aortic valves allow normalization of left ventricular mass in elderly women [J]. Ann Thorac Surg, 2002, 74(6):2022-2025.
67. Yamasaki M, Sasaguri S, Hosoda Y, et al.Long-term results for aortic valve replacement with small aortic annulus [J]. Artificial Organs, 2002, 26(5): 474-478.
68. Hanayama N, Cristakis GT, Mallidi HR, et al. Patient prosthesis mismatch is rare after aortic valve replacement: valve size may be irrelevant [J]. Ann Thorac Surg, 2002,73(6): 1056-1062.
69. Takai H, Yamachika S,Hazama S,et al. Consideration of prosthesis-patient mismatch and left ventricular mass regression after implantation of the Carpentier-Edwards perdicardial valve in elderly Japanese patients: body surface area may be irrelevant [J]. J Artificial Organs,2004,7(4):203-206.
70. Ismeno G, Renzulli A, De Feo M, et al. Standard versus hemodynamic plus 19-mm St Jude Medical aortic valves [J]. J Thorac Cardiovasc Surg, 2001,121(5): 723-728.
71. He GW, Grunkemeier GL, Gately HL, et al. Up to thirty-year survival after aortic valve replacement in the small aortic root [J]. Ann Thorac Surg, 1995,59(5):1056-1062.
72. Knez I, Rienmuller R, Maier R, et al. Left ventricular architecture after valve replacement due to critical aortic stenosis: an approach to dis-/qualify the myth of valve prosthesis-patient mismatch? [J]. Eur J Cardio-Thorac Surg, 2001, 19(6): 797-805.
73. Ennker J, Rosendahl U, Albert A. Stentless bioprostheses in small aortic roots: impact of patient-prosthesis mismatch on survival and quality of life [J]. J Heart Valve Dis, 2005, 14(4): 523-530.
74. Milano AD, Carlo MD,Mecozzi G,et al. Clinical outcome in patients with 19-mm and 21-mm St. Jude aortic prostheses: comparison at long-term follow-up [J]. Ann Thorac Surg,2002,73(1):37-43.
75. Kaiser SP, Melby SJ, Zierer A, et al. Long-term outcomes in valve replacement surgery for infective endocarditis. [J]. Ann-Thorac-Surg. 2007. 83(1): 30-5.
76. Athanasuleas C, Siler W, Buckberg G. Myocardial protection during surgical ventricular restoration. Eur J Cardiothorac Surg. 2006, Suppl 1: S231-7.
77. Ramires FJ, Salemi VM, Ianni BM, et al. Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. J Renin Angiotensin Aldosterone Syst. 2006, 7(3): 162-7.
78. Savini C, Camurri N, Castelli A. Myocardial protection using HTK solution in minimally invasive mitral valve surgery. Heart Surg Forum. 2005, 8(1): E25-7.
79. Fischer UM, Cox CS, Laine GA, et al. Mild hypothermia impairs left ventricular diastolic but not systolic function. J Invest Surg. 2005, 18(6): 291-6.
80. Nemes A, Galema TW, Geleijnse ML, et al. Aortic valve replacement for aortic stenosis is associated with improved aortic distensibility at long-term follow-up. Am Heart J. 2007, 153(1): 147-51.
81. Chowdhury UK, Venkataiya JK, Patel CD. Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease. Am Heart J. 2006, 152(6): 1201-7.
82. Cicekcioglu F, Tutun U, Babaroglu S, et al. Beating heart mitral valve replacement with retrograde coronary sinus perfusion technique. J Cardiovasc Surg (Torino). 2006, 47(5): 575-9.
83. Khan SS, Siegel RJ, DeRobertis MA, et al. Regression of hypertrophy after Carpentier-Edwards pericardial aortic valve replacement [J]. Ann Thorac Surg, 2000, 69(2):531-535.
84. Arata KI, Iguro Y, Masuda H, et al. Long-term follow up in patients receiving a small aortic valve prosthesis [J]. J Heart Valve Dis, 2002,11(6):780-784.
85. Natsuaki M, TohT, Okazaki Y, et al. Influence of St. Jude medical valve in patients with aortic stenosis and small aortic annulus on cardiac function and late survival result [J]. Artificial Organs, 2002,26,(10):840-846.
86. Stike PC,Edwards TJ,Stevan DG,et al.Functional hemodynamic assessment of the 21-mm and 23-mm CarboMedics Top Hat prosthetic valve[J].J Card Surg, 1998, 13(1):98-103.
87. Caus T,Rouviere P,Collart F,et al.late of double-valve replacement wuth biologic or mechanical prostheses [J]. Ann Thorac Surg,2001,71(5 supple 1): s261-s264.
88. Banerjee P,Clark AL,Cleland GF, et al. Diastolic heart failure: a difficult problem in elderly [J]. AM J Geriater Cardiol,2004,13(1): 16-21.
89. Khan S,Bess RL,Rosman HS, et al. Which echocaodiographic Doppler left ventricular diastolic function measurement are most feasible in the clinical echocardiographic laboratory[J].AM J Cardiol,2004,94(8):1099-1101.
90.Talwalkar NG,Lawrie GM,Earle N,et al.Can retrograde cardioplegia alone provide adequate protection for cardiac valve surgery[J].Chest,1999,115:135-139.
91.Tian G,Xiang B,Dai G,et al.The effects of retrograde cardioplegic technique on mgocardial perfusion and energe metabolism[J].Thorac Cardiovasc surg,2000,120(3):544-551.
92.黄元鲁.冠状动脉顺心行灌注心脏不停跳主动脉瓣置换术的心肌保护[J].广西医科大学学报.2004,21(1):82-83.
93.Chocron S,Kalli D,Yunsheng Y,et al.Intermediate warm antegrade intermittent blood cardioplegia compared with cold and warm blood cardioplegia[J].J Thorac Cardiovasc Surg,2000,119(3):610-616.
94.Lajos TI,Esperson EC,Lajos PC,et al.Comparison of cold with warm cardioplegia crystalloid antegrade or retrograde blood[J].Circulation,1993,88(2):344-349.
95.Rueng SP,Buxton BF.Anatomic and hemodynamic considerations influencing the efficiency of retrograde cardioplegia[J].Ann Thorac Surg,2001,71(4):1389-1395.
96.Hirata N,Sakai K,Oh TM,et al.Assessment of myocardial distribution of retrograde and antegrade cardiop legik solution in the same patients[J].Eur J Cardiothorac Surg,1997,12(2):242-247.
97.Arom KV,Emery RW,Petersen RJ,et al.Evalution of 7000+ patients with two different routes of cardioplegia[J].Ann Thorac Surg,1997,63(6):1619-1624.
98.Tian G,Xiang B,Dai G,et al.Retrograde cardioplegia[J].J Thorac Cardiovasc Surg,2003,125(4):872-880.
99.Carrier M,Leung TK,Solymoss BC,et al.Clinical trial of retrograde warm blood reperfusion versus standard cold topical irrigation of transplanted hearts[J].Ann Thorac Surg,1996,61(5):1310-1315.
100.Tehrani H,Masroor S,Lombardi P,et al.Beating heart aortic valve replacement in a pregnant patient[J].J Cardiac Surg,2004,19(1):57-58.
101.潘柏申.心脏标志物的临床应用[J].中华检验医学杂志,2005,28(1):124-126.
102.Micheli A,Chavez E.Ischemia-reperfusion myocardial injury.Arch Cardiolog,2003,73(4):284-290.
103.Kuznetsov AV,Schneeberger S,Seiler RBG et al.Mitochondrial defects and heterogeneous cytochrome c release after cardiac cold ischemia and reperfusion[J].AM J Physiol(Heart Circ Physiol),2004,286(5):H1633-H1641.
104.Bodor GS,Survant L,Voss EM,et al.Cardiac troponin T composition in normal and regenerating human skeletal muscle[J].Clin Chem,1997,43(3):476-84.
105.Hirsch R,Dent CL,Wood MK,et al.Patterns and potential value of cardiac troponin Ielevations after pediatric cardiac operations[J].Ann Thorac Surg,1998,65(5):1394-1399.
106.Cook DJ.Changing temperature management for cardiopulmonary bypass[J].Anesth Analg,1999,88:1254-1271.
107.Piper HM,Dorado GD,Ovize M,et al.A fresh look at reperfusion injury[J].Cardiovasc Res,1998,38(3):291-300.
108.周骐,肖颖彬,陈林.逆灌浅低温氧合血心脏不停跳和冷血心脏麻痹液对心肌代谢影响的临床研究[J].创伤外科杂志,2003,5(2):114-117.
109.Levy JH,Tanaka KA.Inflammatory response to cardiopulmonary bypass[J].Ann Thorac Surg,2003,75(2):S715-20.
110.Munoz R,Laussen PC,Palacio G,et al.Changes in whole blood lactate levels during cardiopulmonary bypass for surgery for congenital cardiac disease:an early indicator of morbidity and moetality.J Thorac Cardiovasc Surg,2000;119:155-162
111.Hashimoto K,Sasaki T,Hachiya T,et al.Influence of cardiopulmonary bypass temperature on circulatory pathophysiology and clinical outcomes[J].Jpn Circ J,2000,64(4):436-444.
112.Lehman JJ,Kelly DP.Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart[J].Clin Exp Pharmacol Physiol,2002,29(4):339-345.
113.Casademont J,Miro O.Electron transport chain defects in heart failure[J].Heart Fail Rev,2002,7(2):131-139.
114.Recchia FA,Mcconnell PI,Bernstein RD,et al.Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog[J].Circ Res,1998,83(10):969-979.
115.Razeghi P,Young ME,Alcorn JL,et al.Metabolic gene expression in fetal and failing human heart [J]. Circulation,2001,104(24):2923-2931.
116. Rosenblatt VN, Montessuit C, Papageorgiou I,et al. Post infarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism [J]. Cardiovasc Res, 2001,52(3):407-416.
117. Liu Q, Docherty JC,Rendell JCT, et al. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation [J]. J Am Coll Cardiol,2002,39(4):718-725.
118. Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial infarcts. Ann Review Biomed Engineer, 2005,7(2): 223-253.
119. Brasselet C, Durand E, Addad F, et al.Collagen and elastin cross-linking: a mechanism of constrictive remodeling after arterial injury [J].AM J Physio(Heart And Circ Physiol), 2005,289(5): H2228-H2233.
1.张宝仁,邹良建,徐志云,等.风湿性瓣膜病二尖瓣与主动脉瓣置换术1154例长期效果分析[J].中华外科杂志,2003,41(4):243-246.
2.张春曦,黄达德,伊红.巨大左室二尖瓣机械瓣置换术后远期随访[J].中国心血管病研究杂志.2005,3(2):138-140.
3.李军,杨康,杨军民,等.合并巨大左室的重症风湿性瓣膜病的外科治疗[J].重庆医学.2004,33(12):1788-1789.
4.于伟勇,张宝仁.联合瓣膜病合并巨大左室的瓣膜替换术[J].上海医学.2000,23(10):599-602.
5.向小勇,李法荫.心脏瓣膜病巨大左室的换瓣治疗经验[J].中国胸心血管外科临床杂志.1996,3(2):88-89.
6.梅举,张宝仁.心脏瓣膜病巨大左室的外科治疗经验[J].中华胸心血管外科杂志.1994,10(4):289-292.
7.Klodas E,sarano ME,Tajik AJ,et al.Arotic regurgitation complicated by extreme left ventricular dilation:long term outcome after surgical correction[J].J Am Coll Cardiol,1996,27(3):670-677.
8.Miller,-G-L.Aortic regurgitation with extreme left ventricular dilation.J Am Coll Cardiol.1996,28(3):798-9.
9.徐志云,张宝仁,朱家麟,等.风心病二尖瓣狭窄合并小左室的瓣膜替换术经验[J].中华胸心血管外科杂志,1997,13(1):1-4.
10.Krayenbuehl HP,Hess O,Monrad ES,et al.Left ventricular myocardial structure in aortic valve disease before intermediate and late after aortic valve replacement[J].Circulation,1989,79(4):744-755.
11.Spinale FG,Ishihra K,Zile M,et al.Structural basis for changes in left ventricular function and geometry because of chronic mitral regurgitation and after correction of volume overload[J].J Thorac Cardiovasc Surg,1993,106(6):1147-1157.
12.Roman MJ,Klein L,Devereux RB,et al.Reversal of left ventricular dilation hypertrophy,and dysfunction by valve replacement in aortic regurgitation[J].Am Heart J,1989,118(3):553-563.
13.Bonow RO,Dott J T,Maron BJ,et al.Long term serial change in left ventricular function and reversal of ventricular dilation after valve replacement for chronic aortic regurgitation[J].Circulation,1988,78(5):1108-1120.
14.Pela G,La Ganna G,Metra M.Long-term changes in left ventricular mass,chamber size and function after valve replacement in patient and sever aortic stenosis and depressed ejection fraction[J].Cardiology,1997,88(4):315-322.
15.Enriquez Sarano M,Tajik AJ,Schaff HV,et al.Echocardiographic prediction of left ventricular function after correction of mitral regurgitation,results and clinical implication[J].J Am Coll Cardiol,1994,24(6):1536-1543.
16.陈勇兵,顾泗荣,王岩,等.小左室二尖瓣的替换术的围手术期的处理[J].中华胸心血管外科杂志,1996,16(4):703-704.
17.沈家宜,严志琨,徐海林,等.巨大左心室的瓣膜病的外科治疗[J].中华胸心血管外科杂志,1999,15(2):72-74.
18.Ren J F,Ksut S,Lighty GW,et al.Mitral valve repair is superior to valve replacement for the early preservation of cardiac function:relation of ventricular geometry to function[J].Am Heart J,1996,131(5):974-981.
19.沈家宜,严志琨,孔颂阳,等.巨大心脏瓣膜替换术围手术期处理[J].上海医学,1996,19(11):631-633.
20.潘晓鸣,薛武军,田普训,等.营养支持在肾移植围手术期的应用.西安交通大学学报:医学版.2007,28(1):97-99.
21.李宁.围手术期营养支持.临床外科杂志.2006,14(9):544-545.
22.黎介寿.围手术营养支持的需要性.肠外与肠内营养.2006,13(3):129-131.
1.Murry CE,Jennings RB,Reimer KA.Preconditioning with ischemia:a delay of lethal cell injury in ischemic myocardium.Circulation,1986,74(5):1124-1136.
2.Marber MS,Latchman DS,Walker JM,et al.Cardiac stress protein elevation 24hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.Circulation,1993,88(3):1264-1272.
3.Barbosa V,Sievers RE,Zaugg CE,et al.Preconditioning ischemia time determines the degree of glycogen depletion and infarct size reduction in rat heart.Am.Heart J.1996,131:224-230.
4.Piot CA,Padmanaban D,Ursell PC,et al.Ischemic preconditioning decreases apoptosis in rat hearts in vivo.Circulation.1997,96:1598-1604.
5.Iliodromitis EK,Kremastinos DT,Katritsis DG,et al.Multiple cycles of preconditioning cause loss of protection in open-chest rabbits.J.Mol.Cell Cadiol.1997,29:915-920.
6.Verdouw PD,Gho BC,Koning MM,et al.Cardioprotection by ischemic and nonischemic myocardial stress and ischemia in remote organs:Implications for the concept of ischemic preconditioning.Ann.N.Y.Acad.Sci.1996,793:27-42.
7.Birnbaum Y,Hale SL,Kloner RA.Ischemic preconditioning at distance:reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit.Circulation.1997,96:1641-1646.
8.Yellon DM,Alkhulaifi AM,Pugsley WB.Preconditioning the human myocardium[J].Lancet,1993,342:276-277.
9.Wu ZK,Tarkka MR,Eloranta J,et al.Effect of ischemic preconditioning on myocardial protection in coronary artery bypass graft patients:can the free radicals act as a trigger for ischemic preconditioning? Chest.2001;119(4):1061-8.
10.Li G,Chen S,Lu E,et al.Ischemic preconditioning improves preservation with cold blood cardioplegia in valve replacement patients.Eur.J.Cardiothorac.Surg.1999;15(5):653-7.
11.姚尖平,张希,吴钟凯等.缺血预处理在心瓣膜置换术中对心肌保护的作用.中国胸心血管外科临床杂志 2006,13(5):311-314.
12. Gunaydin B, Cakici I, Soncul H, et al. Does remote organ ischemia trigger cardiac preconditioning during coronary artery surgery? Pharmacol. Res. 2000, 41:493-496.
13. Kitakaxe M, Hori M. Ischemic preconditioning increase adenosine release and 5'-nucleotidase activity during myocardial ischemic and reperfusion in dogs implication for myocardial salvage. Circulation, 1993, 87: 208-215.
14. Jason N. Peart and John P. Headrick Adenosinergic cardioprotection: Multiple receptors, multiple pathways. Pharmacology & Therapeutics, 2007.
15. Ahmet I, Sawa Y, Nishimura M, et al. Myocardial protection using diadenosine tetraphosphate with pharmacological preconditioning. Ann Thorac Surg , 2000 , 70 (3): 901-905.
16. McCully JD, Uematsu M, Parker RA, et al. Adenosine-enhanced ischemic preconditioning provides enhanced cardioprotection in aged heart. Ann Thorac Surg, 1998,66:2037-2043.
17. Mehta AB, Mardikar HM, Hiregouder NS, et al. Preconditioning the human myocardium with intracoronary adenosine. Indian Hear J, 1998, 50: 397-401.
18. Noma A. ATP-regulated K~+ channels in cardiacmuscle. Nature, 1983;305:147-148.
19. Inoue I, Nagase H, Kishi K, et al. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature, 1991, 352:244-247.
20. Wang X, Wei M, Kuukasjarvi P. Novel pharmacological preconditioning with diazoxide attenuates myocardial stunning in coronary artery bypass grafting. Eur J Cardiothorac Surg. 2003; 24(6): 967-73.
21. Sanada S, Kitakaze M, Asanuma H, et al. Role of mitochondria and sarcolemmal K(ATP)channels in ischemic preconditioning of the canine heart. Am J Physiol Heart Circ Physiol, 2001 280:256-263.
22. Tsuchida A, Miura T, Tanno M, et al. Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemma K(ATP) channels, and protein kinaseC. J Am Coll Cardiol 2002, 40: 1523-1530.
23. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol, 2000, 35: 345-351.
24. Sharony R, Frolkis I, Froylich D. Pharmacological preconditioning with monophosphoryl lipid A improves post ischemic diastolic function and modifies TNF-alpha synthesis. Eur J Cardiothorac Surg. 2005; 27(3): 501-7.
25. Yoshida T, Engelman RM, Engelman DT. Preconditioning of swine heart with monophosphoryl lipid A improves myocardial preservation. Ann Thorac Surg. 2000; 70(3): 895-900.
26. Gyorgy K, Muller B, Vegh A, et al. Triggering role of nitric oxide in the delayed protective effect of monophosphoryl lipid A in rat heart. Br Pharmacol, 1999, 127: 1892-1898.
27. Kehl F, Pagel PS, Krolikowski JG, et al. Is isoflurane-induced preconditioning dose elated. Anesthesiol, 2002, 96(3): 675-680.
28. Li F, Hayes JK, Wong KC, et al. Administration of sevoflurane and isoflurane prior to prolonged global ischemia improves heart function in isolated rat heart. Acta Anaesthesiologica Sinica, 2000, 38(1):113-121.
29. Belhomme D, Peynet J, Lounay JM, et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation, 1999, 100: 340-344.
30. Katsuya T, Lynda M, Ludwig BS, et al. Mechanisms of cardio-protection by volatile anesthetics. Anesthesiology, 2004, 100: 707-721.
31. Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide- sensitive mechanism in the rat heart. Circ Res 1996;78:110-4.
32. Karck M, Tanaka S, Boiling SF, Simon A, Tsung-Ping Su, Oeltgen PR, Haverich A. Myocardial protection by ischemic preconditioning and d-opioid receptor activation in the isolated working rat heart. J Thorac Cardiovasc Surg 2001;122:986-92.
33. Feng J, Li H, Rosenkranz ER. Bradykinin protects the rabbit heart after cardioplegic ischemia via NO-dependent pathways. Ann Thorac Surg. 2000; 70(6): 2119-24.
34. Tom B, Dendorfer A, Danser AH, et al. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int. J. Biochem. Cell Biol. 2003,35: 792-801.
35. Schwarz ER, Montino H, Fleischhauer J, et al. Angiotensin II receptor antagonist EXP3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc. Drugs Ther. 1997, 11:687-695.
36. Miki T, Miura T, Ura N, et al. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. J. Am. Coll. Cardiol. 1996,28:1616-1622.